Allogene Therapeutics ALLO Business Segments — Income Tax
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Allogene Therapeutics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's business segments — income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's business segments — income tax?
- Allogene Therapeutics (ALLO) reported business segments — income tax of $0 in Q4 2025.
- How has Allogene Therapeutics's business segments — income tax changed year-over-year?
- Allogene Therapeutics's business segments — income tax decreased by 100.0% year-over-year, from $110.75K to $0.
- What does business segments — income tax mean?
- This metric reflects the portion of total corporate income tax liability specifically allocated or attributable to the operations of a distinct business segment. It captures the tax impact of segment-level earnings or losses, providing insight into the tax efficiency of the segment's activities. Monitoring this helps stakeholders understand how tax regulations and jurisdictional requirements influence the net contribution of individual business units to the company's bottom line.